incyte | Biopharmaceutical Company | Solutions for Unmet Medical Needs

Keyword	CPC	PCC	Volume	Score	Length of keyword
incyte	0.06	0.1	3408	25	6

Keyword	CPC	PCC	Volume	Score
incyte	0.27	0.1	4756	87
incyte corporation	0.62	0.2	8316	92
incyte stock	0.67	0.3	1089	26
incyte diagnostics	1.59	0.5	5262	70
incytecares	0.26	0.3	7355	62
incyte pharmaceuticals	0.1	0.1	2066	60
incyte stock news	0.1	0.2	7197	80
incyte pipeline	0.34	0.5	4561	66
incyte careers	1.38	0.2	9878	94
incyte pathology	1.45	1	3134	78
incyte lab test menu	0.91	0.5	7864	80
incytediagnostics itx	0.3	1	9711	58
incyte stock price	0.89	0.3	8269	65
incytediagnostics.ixt.com	0.58	0.1	7145	67
incyte lab	1.75	0.3	8338	19
incyte test menu	2	0.3	6002	69
incyte biosciences	1.14	0.9	3736	53
incyte diagnostics spokane	0.3	1	584	24
incyte yverdon	1.3	0.4	9585	93
incyte annual report	0.48	0.7	9442	15

Search Results related to incyte on Search Engine

Biopharmaceutical Company | Solutions for Unmet Medical Needs | Incyte…
incyte.com

https://incyte.com/

WEBA source for information and support. Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines..

DA: 15 PA: 53 MOZ Rank: 88

Incyte - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Incyte

WEBIncyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware.

DA: 74 PA: 42 MOZ Rank: 21

Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology ... - Incyte
incyte.com

https://incyte.com/what-we-do/pharmaceutical-portfolio

WEBFeb 13, 2024 · Explore Our Science. We have a breadth of clinical programs within our portfolio across Myeloproliferative Neoplasms (MPNs) and Graft-Versus-Host Disease (GVHD), General Hematology/Oncology, Dermatology and other Inflammation & Autoimmunity (IAI), and Partnered Programs.

DA: 60 PA: 84 MOZ Rank: 67

Global Biopharmaceutical Company | Incyte.com
incyte.com

https://incyte.com/who-we-are/biopharmaceutical-research

WEBWHAT WE DO. Incyte is a global biopharmaceutical company that has created a robust and diversified portfolio of marketed products and clinical candidates in oncology, inflammation, and autoimmunity.

DA: 70 PA: 22 MOZ Rank: 13

Investors | Incyte
incyte.com

https://investor.incyte.com/

WEBMar 29, 2024 · Investors. Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

DA: 18 PA: 33 MOZ Rank: 55

Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) …
incyte.com

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-fda-approval-zynyztm-retifanlimab-dlwr

WEBMar 22, 2023 · PDF Version. — First regulatory approval for Incyte PD-1 inhibitor based on the results of the POD1UM-201 trial. — Zynyz is also being studied in additional tumor types and in combination with other Incyte pipeline compounds.

DA: 43 PA: 72 MOZ Rank: 64

Oncology Research | Targeted & Immunotherapy For Cancer | Incyte…
incyte.com

https://incyte.com/what-we-do/oncology

WEBIncyte is a leader in the discovery and development of therapies for patients with myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). We have multiple clinical trials evaluating monotherapy and combination strategies to improve and expand treatments for patients with MPNs and GVHD.

DA: 38 PA: 66 MOZ Rank: 64

Incyte Reports 2022 Fourth Quarter and Year-end Financial …
incyte.com

https://investor.incyte.com/news-releases/news-release-details/incyte-reports-2022-fourth-quarter-and-year-end-financial

WEBFeb 7, 2023 · Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs. – Total FY'22 net product revenues grew 18% to $2.75 billion; total FY'22 revenues of $3.4 billion (+14% Y/Y) – Jakafi® (ruxolitinib) net revenues of $647 million (+9% Y/Y) in Q4'22 and $2.41 …

DA: 39 PA: 95 MOZ Rank: 77

Drug Development & Scientific Innovation in Oncology and ... - Incyte
incyte.com

https://incyte.com/what-we-do/drug-development

WEBIncyte’s team of biologists and chemists are pursuing new areas in drug discovery and development in order to help patients. Drug Development & Scientific Innovation in Oncology and Inflammation & Autoimmunity | Incyte.com

DA: 53 PA: 16 MOZ Rank: 49

Incyte Corp (INCY) Stock Price & News - Google Finance
google.com

https://www.google.com/finance/quote/INCY:NASDAQ

WEBGet the latest Incyte Corp (INCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

DA: 11 PA: 95 MOZ Rank: 87